Biogen looks to ex-U.S. markets for growth

Biogen Inc. (NASDAQ:BIIB) perceives greater long-term growth opportunities than anticipated in the EU and emerging markets, the company's CEO Michel Vounatsos said on its earnings call Tuesday, while noting that the U.S. market remains its key driver of growth.

The bellwether reported an overall increase in ex-U.S. sales in the first quarter, even as it saw a decline in U.S. sales for some drugs, including spinal muscular atrophy

Read the full 677 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers